Figure 6 | Scientific Reports

Figure 6

From: A high-throughput cell-based assay pipeline for the preclinical development of bacterial DsbA inhibitors as antivirulence therapeutics

Figure 6

Absorbance-based UPEC motility in the presence of DsbA inhibitors. (A) Motility curves and (B) motility dose–response curve of UPEC CFT073 on LB agar (0.25%) containing DsbA inhibitor F1 (1–0.1 mM) or (C) DsbA inhibitors F2 (0.5 mM), F4 (0.5 mM) and 0.4% DMSO (vehicle control), monitored spectrophotometrically during incubation at 37 °C over 15 h. The immotile isogenic dsbA null strain (KO) is shown as a control (A). Data are shown as absorbance 600 nm (A and C), and normalised gradient (calculated from the treatment slopes of (A), listed in Table 1) (B), with the mean ± SD of 3 biological replicates plotted at each time point.

Back to article page